Fibroblast growth factor 21 serum concentrations in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2).
| Autor: | Walus-miarka, M., Idzior-Walus, B., Kapusta, M., Trojak, A., Miarka, P., Malecki, M.T. |
|---|---|
| Zdroj: | In Atherosclerosis August 2018 275:e151-e151 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect